Vemurafenib was studied in nonmelanoma BRAF V600–mutant tumors, and preliminary activity was identified in NSCLC, Erdheim–Chester disease, and Langerhans cell histiocytosis, among other cancers (Hyman et al. 2015). Here, BRAF is linked to Langerhans cell histiocytosis.